MX2024006403A - Dispositivo farmaceutico para uso en administracion intranasal. - Google Patents
Dispositivo farmaceutico para uso en administracion intranasal.Info
- Publication number
- MX2024006403A MX2024006403A MX2024006403A MX2024006403A MX2024006403A MX 2024006403 A MX2024006403 A MX 2024006403A MX 2024006403 A MX2024006403 A MX 2024006403A MX 2024006403 A MX2024006403 A MX 2024006403A MX 2024006403 A MX2024006403 A MX 2024006403A
- Authority
- MX
- Mexico
- Prior art keywords
- powder composition
- compositions
- applicator
- months
- actuation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 8
- 239000000843 powder Substances 0.000 abstract 5
- -1 lactose or trehalose Chemical class 0.000 abstract 3
- 108060003345 Adrenergic Receptor Proteins 0.000 abstract 2
- 102000017910 Adrenergic receptor Human genes 0.000 abstract 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 abstract 1
- 229930182837 (R)-adrenaline Natural products 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 239000005913 Maltodextrin Substances 0.000 abstract 1
- 229920002774 Maltodextrin Polymers 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 230000036783 anaphylactic response Effects 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 239000012876 carrier material Substances 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229960005139 epinephrine Drugs 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 229940035034 maltodextrin Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229940075993 receptor modulator Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
- 229940032085 sucrose monolaurate Drugs 0.000 abstract 1
- 150000003445 sucroses Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/0007—Special media to be introduced, removed or treated introduced into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fire-Extinguishing By Fire Departments, And Fire-Extinguishing Equipment And Control Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2117016.2A GB202117016D0 (en) | 2021-11-25 | 2021-11-25 | New pharmaceutical device |
| PCT/GB2022/052983 WO2023094816A1 (en) | 2021-11-25 | 2022-11-25 | Pharmaceutical device for use in intranasal administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006403A true MX2024006403A (es) | 2024-08-15 |
Family
ID=79602091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006403A MX2024006403A (es) | 2021-11-25 | 2022-11-25 | Dispositivo farmaceutico para uso en administracion intranasal. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12303472B2 (https=) |
| EP (1) | EP4237051A1 (https=) |
| JP (1) | JP2024542520A (https=) |
| KR (1) | KR20240111769A (https=) |
| CN (2) | CN118695851A (https=) |
| AU (1) | AU2022395916A1 (https=) |
| CA (1) | CA3238847A1 (https=) |
| GB (1) | GB202117016D0 (https=) |
| IL (1) | IL313014A (https=) |
| MX (1) | MX2024006403A (https=) |
| WO (1) | WO2023094816A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3962455T (pt) | 2020-05-18 | 2022-10-13 | Orexo Ab | Nova composição farmacêutica para entrega de fármacos |
| US12414916B2 (en) | 2021-06-10 | 2025-09-16 | Belhaven BioPharma Inc. | Dry powder formulations of epinephrine and associated methods |
| AR127780A1 (es) | 2021-11-25 | 2024-02-28 | Orexo Ab | Nueva composición farmacéutica que comprende adrenalina |
| TW202502309A (zh) * | 2023-05-31 | 2025-01-16 | 瑞典商奥瑞克索股份公司 | 包含腎上腺素激導性受體調節劑的噴霧乾燥之組合物 |
| US20260108686A1 (en) | 2024-10-21 | 2026-04-23 | Belhaven BioPharma Inc. | Compositions, devices, and methods for intranasal delivery of dry powder epinephrine |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE759520A (fr) | 1969-11-28 | 1971-04-30 | Aspro Nicholas Ltd | Compositions d'aspirine |
| US5082669A (en) | 1989-07-20 | 1992-01-21 | Dainippon Pharmaceutical Co., Ltd. | Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked |
| SE8904296D0 (sv) | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Transdermal system |
| ATE196427T1 (de) | 1993-12-06 | 2000-10-15 | Takeda Chemical Industries Ltd | Zusammensetzung mit verbesserter wasserlöslichkeit, enthaltend eine wasserunlösliche oder an wasser schwerunlösliche verbindung |
| CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
| DE19518810A1 (de) | 1995-05-26 | 1996-11-28 | Bayer Ag | Nasal-Applikator |
| CN1106888C (zh) | 1998-03-10 | 2003-04-30 | 瓦卢瓦股份有限公司 | 容器、容器的灌注方法及容器中流体制品的分配装置 |
| JP3422775B2 (ja) | 1998-07-08 | 2003-06-30 | キリン−アムジエン・インコーポレーテツド | 高分子医薬品含有粉末状経粘膜投与製剤 |
| JP2000178184A (ja) | 1998-12-17 | 2000-06-27 | Lion Corp | 粒状組成物、錠剤及び粒状組成物の製造方法 |
| GB9908921D0 (en) | 1999-04-19 | 1999-06-16 | Britannia Pharmaceuticals Ltd | Spray dispenser for opiod antagonists |
| US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| GB0003782D0 (en) | 2000-02-17 | 2000-04-05 | Dumex Ltd As | Process |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| KR20010107754A (ko) | 2000-05-26 | 2001-12-07 | 민경윤 | 경구투여용 속용정의 제조 방법 |
| FR2817847B1 (fr) | 2000-12-08 | 2003-03-28 | Tebro | Dispositif de distribution de produit fluide ou pulverulent |
| IN192750B (https=) | 2000-12-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
| US6443152B1 (en) * | 2001-01-12 | 2002-09-03 | Becton Dickinson And Company | Medicament respiratory delivery device |
| LU90825B1 (en) | 2001-09-06 | 2003-03-07 | Iee Sarl | Method for the determination of one or more parameters of a seat passenger |
| ITMI20012174A1 (it) | 2001-10-18 | 2003-04-18 | Univ Parma | Polvere per somministrazione nasale di farmaci |
| FR2834212B1 (fr) | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
| GB0201367D0 (en) | 2002-01-22 | 2002-03-13 | Ml Lab Plc | Composition |
| AU2006207868A1 (en) * | 2002-03-20 | 2006-09-28 | Alkermes, Inc. | Method and apparatus for producing dry particles |
| SI1531794T1 (sl) | 2002-06-28 | 2017-12-29 | Civitas Therapeteutics, Inc. | Epinefrin za vdihavanje |
| WO2004054511A2 (en) | 2002-12-13 | 2004-07-01 | The Regents Of The University Of California | Analgesic combination comprising nalbuphine |
| EP2343045A3 (en) | 2003-02-24 | 2011-09-21 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
| JP4739217B2 (ja) | 2003-05-07 | 2011-08-03 | サムヤン コーポレイション | 速く溶ける錠剤を製造するための高可塑性顆粒 |
| US7954491B2 (en) | 2003-06-13 | 2011-06-07 | Civitas Therapeutics, Inc. | Low dose pharmaceutical powders for inhalations |
| CN100471497C (zh) | 2003-06-25 | 2009-03-25 | 中国人民解放军军事医学科学院毒物药物研究所 | 盐酸纳洛酮鼻粉剂 |
| US20050042178A1 (en) | 2003-08-18 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder |
| CN100515511C (zh) | 2003-10-09 | 2009-07-22 | 株式会社;生命科学活效 | 鼻腔用粉状药剂施药装置 |
| WO2005044186A2 (en) | 2003-10-28 | 2005-05-19 | Glaxo Group Limited | Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same |
| CN1640402A (zh) | 2004-01-02 | 2005-07-20 | 广东奇方药业有限公司 | 一种稳定的纳洛酮粉针剂 |
| IL159729A0 (en) | 2004-01-06 | 2004-06-20 | Doron I Friedman | Non-aqueous composition for oral delivery of insoluble bioactive agents |
| US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
| US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
| CN1615867A (zh) | 2004-10-22 | 2005-05-18 | 北京阳光润禾科技有限公司 | 注射用盐酸纳洛酮冻干粉针制剂 |
| WO2006101536A1 (en) | 2004-11-04 | 2006-09-28 | Akina, Inc. | Fast-melting tablets having taste-masking and sustained release properties |
| CN1781479B (zh) | 2004-12-02 | 2010-06-30 | 和记黄埔医药企业有限公司 | 一种马蔺子素分散体系及其制备方法 |
| US20080317863A1 (en) | 2005-02-10 | 2008-12-25 | Christer Nystrom | Pharmaceutical Compositions Useful in the Transmucosal Administration of Drugs |
| KR101233235B1 (ko) | 2005-08-26 | 2013-02-15 | 에스케이케미칼주식회사 | 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법 |
| US20070202163A1 (en) | 2005-09-09 | 2007-08-30 | Mutasem Rawas-Qalaji | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
| CN1939358A (zh) | 2005-09-30 | 2007-04-04 | 江西本草天工科技有限责任公司 | 肿节风分散片 |
| CN1813739A (zh) | 2005-11-25 | 2006-08-09 | 王颖 | 一种注射用盐酸纳美芬冻干粉针制剂 |
| CA2640165A1 (en) | 2006-01-27 | 2007-08-02 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivid Ed Trinity Of Queen Elizabeth Near Dublin | A method of producing porous microparticles |
| WO2007096906A2 (en) | 2006-02-27 | 2007-08-30 | Panacea Biotec Ltd. | Novel buccoadhesive compositions and process of preparation thereof |
| US20100226979A1 (en) | 2006-03-21 | 2010-09-09 | Jubilant Organosys Limited | Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate |
| CN101460150B (zh) | 2006-03-31 | 2014-02-12 | 鲁比康研究私人有限公司 | 用于口腔崩解片剂的可直接压片复合物 |
| PL2061427T3 (pl) | 2006-09-15 | 2011-12-30 | Echo Pharmaceuticals Bv | Granulat zawierający substancję farmaceutycznie aktywną i emulgator oraz sposób jego wytwarzania |
| US20080269347A1 (en) | 2006-09-28 | 2008-10-30 | Azopharma, Inc. | Epinephrine formulations |
| JP2010515753A (ja) | 2007-01-10 | 2010-05-13 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 肺内送達用免疫抑制剤組成物の送達の増強 |
| WO2009040595A1 (en) | 2007-09-28 | 2009-04-02 | Wockhardt Research Centre | Multi-dose pharmaceutical composition of analgesic for nasal administration |
| CN102083467B (zh) | 2008-03-11 | 2013-12-25 | Aska制药株式会社 | 固体分散体及其药物组合物、以及它们的制备方法 |
| US20090246256A1 (en) | 2008-03-27 | 2009-10-01 | Al-Ghananeem Abeer M | Compositions and Methods for Transmucosal Delivery of Lofexidine |
| US20090264530A1 (en) | 2008-04-16 | 2009-10-22 | Nickell Robert P | Combined nsaid and acetaminophen formulation and method |
| US8715715B2 (en) | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
| ES2661215T3 (es) | 2009-05-20 | 2018-03-28 | Aeras | Composiciones víricas; inmunógenas; secadas por pulverización; estables |
| PL3111927T3 (pl) | 2009-05-29 | 2020-06-29 | Pearl Therapeutics, Inc. | Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy |
| EP2266563A1 (en) | 2009-06-11 | 2010-12-29 | Charité-Universitätsmedizin Berlin (Charité) | Use of opioid receptor antagonists for acute treatment of paraphilic arousal states |
| WO2010144865A2 (en) | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| WO2011013003A2 (en) | 2009-07-31 | 2011-02-03 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal granisetron and nasal applicator |
| DK2480197T3 (en) | 2009-09-25 | 2016-01-25 | Reddys Lab Ltd Dr | Compositions containing triptanforbindelser |
| RU2013113627A (ru) | 2010-08-27 | 2014-10-10 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтическая композиция и ее введения |
| CN103200938B (zh) | 2010-08-30 | 2018-07-31 | 普马特里克斯营业公司 | 干燥粉末配方及用于治疗肺部疾病的方法 |
| MX2013003522A (es) | 2010-10-01 | 2013-05-22 | Cipla Ltd | Composicion farmaceutica. |
| CN107028900A (zh) | 2010-12-02 | 2017-08-11 | 艾戴尔医药公司 | 快速分散颗粒、口腔崩解片以及方法 |
| DK2675301T3 (en) | 2011-02-18 | 2019-03-25 | Biolingus Ip Llc | PROCEDURE FOR PRODUCING PRODUCTS CONTAINING STABILIZED ACTIVE SUBSTANCES |
| MY194947A (en) | 2011-05-13 | 2022-12-27 | Euro Celtique Sa | Intranasal pharmaceutical dosage forms comprising naloxone |
| BR112014028431B1 (pt) | 2012-05-11 | 2022-01-11 | Activus Pharma Co., Ltd | Nanopó de composto orgânico, método para produzir o mesmo e suspensão |
| EP2861224A4 (en) | 2012-06-15 | 2015-11-18 | Univ Nova Southeastern | EPINEPHRINNANOPARTICLES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE USE THEREOF FOR TREATING SUFFERING SUFFERING TO EPINEPHRIN |
| US9789071B2 (en) * | 2012-06-27 | 2017-10-17 | G2B Pharma, Inc. | Intranasal formulation of epinephrine for the treatment of anaphylaxis |
| EP3248642B1 (en) | 2012-06-28 | 2020-04-08 | The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services | Nasal dry powder delivery system for vaccines and other treatment agents |
| FR3007992B1 (fr) | 2013-07-05 | 2018-01-26 | Aptar France Sas | Dispositif de distribution de produit fluide ou pulverulent. |
| MX2016002705A (es) | 2013-09-03 | 2016-09-06 | G2B Pharma Inc | Formulacion intranasal para el tratamiento por reanimacion cardiopulmonar (rcp), mantenimiento cardiaco vital (cls), de anafilaxia y/o reacciones anafilactoides. |
| EP2886107A1 (en) | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| WO2015095389A1 (en) | 2013-12-18 | 2015-06-25 | Aegis Therapeutics, Llc | Compositions for drug administration |
| CA2875384A1 (en) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| US9480644B2 (en) | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
| NZ724756A (en) | 2014-04-04 | 2023-07-28 | Ai Therapeutics Inc | An inhalable rapamycin formulation for treating age-related conditions |
| US20190008759A1 (en) | 2014-07-03 | 2019-01-10 | Darren Rubin | Safer and more effective methods of transmucosal delivery for raising blood pressure and stimulating the body |
| US11135155B2 (en) | 2014-07-08 | 2021-10-05 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| EP3174534A1 (en) | 2014-08-01 | 2017-06-07 | KRKA, d.d., Novo mesto | Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters |
| WO2016044813A1 (en) * | 2014-09-18 | 2016-03-24 | Virun, Inc. | Pre-spray emulsions and powders containing non-polar compounds |
| WO2016055544A1 (en) | 2014-10-08 | 2016-04-14 | Eratech S.R.L. | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation |
| EP3220893B1 (en) | 2014-11-14 | 2023-06-07 | Asoltech Srl | Composition based on coq10 |
| EP3025705B8 (en) | 2014-11-25 | 2018-11-28 | Sanofi Ilaç Sanayi ve Ticaret Anonim Sirketi | Stable ivabradine formulations |
| CN104547220A (zh) | 2014-12-30 | 2015-04-29 | 陈宏� | 一种治疗儿童视觉疲劳的中药组合物及其制剂 |
| US10166197B2 (en) | 2015-02-13 | 2019-01-01 | St. John's University | Sugar ester nanoparticle stabilizers |
| BR112017014994B1 (pt) | 2015-02-17 | 2023-12-19 | Eli Lilly And Company | Composições em pó nasal para tratamento de hipoglicemia, seu uso e seus métodos de preparação, e aplicador nasal |
| US20170189352A1 (en) | 2015-03-13 | 2017-07-06 | Par Pharmaceutical, Inc. | Epinephrine formulations |
| AU2015390471A1 (en) | 2015-04-08 | 2017-11-09 | John KLASSEN | Pharmaceutical compositions of polyanionic and non-ionic cyclodextrin-based dendrimers and uses thereof |
| HK1251998A1 (zh) | 2015-05-01 | 2019-05-10 | Civitas Therapeutics, Inc. | 佐米曲普坦肺部给药粉 |
| US10039710B2 (en) | 2015-09-18 | 2018-08-07 | Insys Development Company, Inc. | Epinephrine spray formulations |
| AU2017210319A1 (en) | 2016-01-20 | 2018-08-23 | Flurry Powders, Llc | Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation |
| ITUB20161027A1 (it) | 2016-02-24 | 2017-08-24 | Altergon Sa | Preparazioni farmaceutiche oromucosali ad elevata biodisponibilita’ a base di ciclodestrina e sucralosio |
| WO2017158439A1 (en) | 2016-03-16 | 2017-09-21 | Omegatri As | Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production |
| US20170312226A1 (en) | 2016-04-28 | 2017-11-02 | Ascent Pharmaceuticals, Inc. | Pharmaceutical dosage forms |
| US11903951B2 (en) | 2016-06-03 | 2024-02-20 | M et P Pharma AG | Nasal pharmaceutical compositions with a porous excipient |
| WO2017218918A1 (en) | 2016-06-17 | 2017-12-21 | Ys Pharmtech | Stabilization of epinephrine formulations |
| WO2018009532A1 (en) * | 2016-07-06 | 2018-01-11 | Mccormick & Company, Incorporated | Natural encapsulation flavor products |
| EP3493789A2 (en) | 2016-08-05 | 2019-06-12 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical powder compositions |
| JP2020500081A (ja) | 2016-09-28 | 2020-01-09 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | オピオイドを送達する経皮薬剤送達装置 |
| WO2018064672A1 (en) | 2016-09-30 | 2018-04-05 | Opiant Pharmaceuticals, Inc. | Treatment with intranasal naloxone |
| US20180092839A1 (en) | 2016-10-03 | 2018-04-05 | Lance L. Gooberman | Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders |
| CA3043028A1 (en) | 2016-11-09 | 2018-05-17 | Opiant Pharmaceuticals, Inc. | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions |
| IL312012A (en) | 2016-11-18 | 2024-06-01 | Opiant Pharmaceuticals Inc | Compositions and methods for the treatment of opioid overdose |
| WO2018148382A1 (en) | 2017-02-10 | 2018-08-16 | Mucodel Pharma Llc | Chemically stable compositions of a pharmaceutical active agent in a multi-chambered delivery system for mucosal delivery |
| CN111050760A (zh) | 2017-04-17 | 2020-04-21 | 希克玛制药美国公司 | 肾上腺素喷雾制剂 |
| EP3668490A4 (en) | 2017-08-20 | 2021-06-09 | Formulex Pharma Innovations Ltd. | Dry powder compositions for intranasal delivery |
| US20180193332A1 (en) | 2017-10-09 | 2018-07-12 | Adapt Pharma Operations Limited | Low-temperature stable opioid antagonist solutions |
| WO2019139865A1 (en) | 2018-01-10 | 2019-07-18 | Insys Development Company. Inc. | Methods of stabilizing epinephrine |
| WO2019157099A1 (en) | 2018-02-06 | 2019-08-15 | Aegis Therapeutics, Llc | Intranasal epinephrine formulations and methods for the treatment of disease |
| WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
| EP3806827A4 (en) | 2018-06-13 | 2022-03-23 | Hikma Pharmaceuticals USA Inc. | EPINEPHRINE SPRAY FORMULATIONS |
| US20230014352A1 (en) | 2019-03-29 | 2023-01-19 | The Regents Of The University Of California | Inhaled statins as bronchodilators to improve lung function in respiratory diseases |
| US10653690B1 (en) | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| US10729687B1 (en) | 2019-07-09 | 2020-08-04 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| FR3098420B1 (fr) | 2019-07-10 | 2021-07-09 | Aptar France Sas | Dispositif de distribution nasale de poudre |
| US11400045B2 (en) | 2020-03-16 | 2022-08-02 | Nasus Pharma Ltd. | Treatment with powdered intranasal epinephrine |
| PT3962455T (pt) * | 2020-05-18 | 2022-10-13 | Orexo Ab | Nova composição farmacêutica para entrega de fármacos |
| FR3121047B1 (fr) | 2021-03-29 | 2023-07-14 | Aptar France Sas | Dispositif de distribution nasale de poudre |
| US11617716B2 (en) | 2021-06-10 | 2023-04-04 | Belhaven BioPharma Inc. | Dry powder formulations of epinephrine and associated methods |
| AR127780A1 (es) * | 2021-11-25 | 2024-02-28 | Orexo Ab | Nueva composición farmacéutica que comprende adrenalina |
-
2021
- 2021-11-25 GB GBGB2117016.2A patent/GB202117016D0/en not_active Ceased
-
2022
- 2022-11-25 CA CA3238847A patent/CA3238847A1/en active Pending
- 2022-11-25 CN CN202280077963.4A patent/CN118695851A/zh active Pending
- 2022-11-25 JP JP2024530531A patent/JP2024542520A/ja active Pending
- 2022-11-25 EP EP22813699.0A patent/EP4237051A1/en active Pending
- 2022-11-25 KR KR1020247019617A patent/KR20240111769A/ko active Pending
- 2022-11-25 WO PCT/GB2022/052983 patent/WO2023094816A1/en not_active Ceased
- 2022-11-25 MX MX2024006403A patent/MX2024006403A/es unknown
- 2022-11-25 IL IL313014A patent/IL313014A/en unknown
- 2022-11-25 AU AU2022395916A patent/AU2022395916A1/en active Pending
- 2022-11-25 CN CN202280078148.XA patent/CN118678979A/zh active Pending
-
2023
- 2023-05-24 US US18/323,115 patent/US12303472B2/en active Active
-
2025
- 2025-04-25 US US19/189,960 patent/US20250262174A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024542520A (ja) | 2024-11-15 |
| AU2022395916A1 (en) | 2024-05-30 |
| CA3238847A1 (en) | 2023-06-01 |
| CN118678979A (zh) | 2024-09-20 |
| WO2023094816A1 (en) | 2023-06-01 |
| KR20240111769A (ko) | 2024-07-17 |
| EP4237051A1 (en) | 2023-09-06 |
| GB202117016D0 (en) | 2022-01-12 |
| US12303472B2 (en) | 2025-05-20 |
| CN118695851A (zh) | 2024-09-24 |
| IL313014A (en) | 2024-07-01 |
| US20250262174A1 (en) | 2025-08-21 |
| US20230310349A1 (en) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006403A (es) | Dispositivo farmaceutico para uso en administracion intranasal. | |
| US12414993B2 (en) | Formulations and uses thereof | |
| MX2024006188A (es) | Nueva composicion farmaceutica que comprende adrenalina. | |
| JP5731446B2 (ja) | 局所用生体付着性製剤 | |
| ES2248042T5 (es) | Composición tópica que comprende n-acetilglucosamina. | |
| CY1123334T1 (el) | Σκευασματα φιναστεριδης για αποδεσμευση φαρμακου στα μαλλια και στο τριχωτο της κεφαλης | |
| US20220287946A1 (en) | Anhydrous skin care composition comprising retinol and/or bakuchiol | |
| AR110986A2 (es) | Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso | |
| MX349176B (es) | Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo. | |
| RU2008145908A (ru) | Пригодный к распылению адгезивный к коже/слизистой оболочке препарат гелевого типа и система для введения с использованием препарата | |
| ECSP099635A (es) | Formulaciones líquidas que forman una capa dérmica para la liberación de fármacos a la piel | |
| EA201190127A1 (ru) | Фармацевтические составы нитазоксанида с контролируемым высвобождением | |
| BR0318319A (pt) | métodos de preparação e formulações/composições sustentadas pelo uso de dimeticona como veìculo | |
| SV2004001418A (es) | Formulaciones farmaceuticas de 5,7,14-triazaciclo 10.3.1.0.2,11.04,9) -hexadeca-2(11),3,5,7,9-pentaeno" ref.pc 23248 | |
| HRP20040323C1 (hr) | Oralni oblici davanja propiverina ili njegovih farmaceutski prihvatljivih soli s produljenim oslobađanjem djelotvone supstance | |
| KR20100122511A (ko) | 손 소독 패치 | |
| AR037560A1 (es) | Formulacion de altas dosis de ibandronato | |
| JP2019026641A (ja) | 外用組成物、外用組成物の安定化方法及び混合製剤用組成物 | |
| AU2015273123A1 (en) | Silicone-based biophotonic compositions and uses thereof | |
| CL2013003630A1 (es) | Formulacion farmaceutica liquida que comprende nitisinona y un tampon de acido citrico que tien un ph en el rango de 2,5 a 3,5, de preferencia 3,0; y su uso para el tratamiento de tirosemia, enfermedad de parkinson, depresion, entre otros. | |
| KR20200002669A (ko) | 광 및 글루코사민 하이드로클로라이드를 사용하여 피부 병태를 치료하기 위한 조성물 및 방법 | |
| AR021459A1 (es) | PARCHE QUE CONTIENE ESTRADIOL PARA LA APLICACIoN PERCUTÁNEA DE HORMONAS. | |
| AR064262A1 (es) | Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato | |
| AR039895A1 (es) | Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla | |
| BRPI0608334A2 (pt) | uso de uma formulação de clobetasol em lìquido pulverizado para o tratamento de psorìase |